94 research outputs found
Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI.
Recent research in autism spectrum disorder (ASD) has aroused interest in anterior cingulate cortex and in the neurometabolite glutamate. We report two studies of pregenual anterior cingulate cortex (pACC) in pediatric ASD. First, we acquired in vivo single-voxel proton magnetic resonance spectroscopy ((1)H MRS) in 8 children with ASD and 10 typically developing controls who were well matched for age, but with fewer males and higher IQ. In the ASD group in midline pACC, we found mean 17.7% elevation of glutamate + glutamine (Glx) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (Cr). We then performed a larger (26 subjects with ASD, 16 controls) follow-up study in samples now matched for age, gender, and IQ using proton magnetic resonance spectroscopic imaging ((1)H MRSI). Higher spatial resolution enabled bilateral pACC acquisition. Significant effects were restricted to right pACC where Glx (9.5%, p<0.05), Cr (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the ASD sample were elevated above control. These two independent studies suggest hyperglutamatergia and other neurometabolic abnormalities in pACC in ASD, with possible right-lateralization. The hyperglutamatergic state may reflect an imbalance of excitation over inhibition in the brain as proposed in recent neurodevelopmental models of ASD
K 1-6: an asymmetric planetary nebula with a binary central star
We present new imaging data and archival multiwavelength observations of the
little studied emission nebula K 1-6 and its central star. Narrow-band images
in H-alpha (+ [NII]) and [OIII] taken with the Faulkes Telescope North reveal a
stratified, asymmetric, elliptical nebula surrounding a central star which has
the colours of a late G- or early K-type subgiant or giant. GALEX ultraviolet
images reveal a very hot subdwarf or white dwarf coincident in position with
this star. The cooler, optically dominant star is strongly variable with a
period of 21.312 +/- 0.008 days, and is possibly a high amplitude member of the
RS CVn class, although an FK Com classification is also possible. Archival
ROSAT data provide good evidence that the cool star has an active corona. We
conclude that K 1-6 is most likely an old bona fide planetary nebula at a
distance of ~1.0 kpc, interacting with the interstellar medium, and containing
a binary or ternary central star. The observations and data analyses reported
in this paper were conducted in conjunction with Year 11 high school students
as part of an Australian Research Council Linkage Grant science education
project, denoted Space To Grow, conducted jointly by professional astronomers,
educational researchers, teachers, and high-school students.Comment: 13 pages, 5 figures, accepted by the Publications of the Astronomical
Society of Australia (PASA
Requirements for physician competencies in allergy: key clinical competencies appropriate for the care of patients with allergic or immunologic diseases
Egypt J Pediatr Allergy Immunol 2009; 7(1): 33-3
Mars Express and Trace Gas Orbiter â status, science highlights, plans
Mars Express
With almost two decades of Mars observation behind it, Mars Express remains a dependable and highly productive mission.
Recent science highlights include (1) continued mapping of subsurface reflectors beneath the south polar layered ice deposits, and associated work to explain the cause of these reflections; (2) a global map of minerals on Mars with 200 m/px resolution, obtained from analysis of infrared spectra; (3) release of 50 m resolution Digital Elevation Models based on HRSC stereo topography for quadrangles covering an ever-increasing proportion of the global surface; (4) detailed characterization of the landing sites of the ESA, NASA and Chinese rovers; (5) a global climatology of ozone and water from both nadir and occultation observations and its relation to atmospheric dust; (6) transient atmospheric phenomena, such as a recurrent orographic cloud feature at Arsia Mons; (7) detailed investigation of the ionospheric structure, its variability, and coupling to the lower atmosphere; (8) continued monitoring of both the upstream solar wind conditions and of downstream escaping ions; (9) detailed study of Phobos during flybys at altitudes as low as 50 km.
Spacecraft and instrument teams continue to implement new and improved observation modes. One example is new MARSIS instrument software which now allows raw data to be returned from much longer subsurface sounding passes, improving the search for basal reflectors beneath polar ice caps; another example is mutual radio occultation observations between Mars Express and ExoMars Trace Gas Orbiter, potentially providing vertical profiles of ionospheric electron content with good spatial and temporal coverage.
ExoMars Trace Gas Orbiter
TGO has now completed two full Martian years of observations.
Highlights include (1) continuing non-detection of methane, with upper limits as low as 20 ppt by volume. Reconciling this continued non-detection by TGO with the background levels of several hundred ppt in Gale crater by MSL remains an enigma, stimulating further research. (2) detection of HCl, the first reported halogen-containing species in the atmosphere of Mars. (3) further detail of the transport of water to high altitudes, a critical step in the escape of water from Mars. (4) mapping of atomic hydrogen in the top 1-2 m of regolith, indicative of water ice and hydrated minerals, suggesting surprisingly high abundances of subsurface water ice in low latitude regions including one in central Valles Marineris; and (5) continued acquisition of 5 m colour imagery and digital elevation models over a wide range of terrain and target types, including landing site characterization.
Future plans: Mission extension cases for both missions have been submitted for the years 2023-2025 and 2026-2028. The extension of the observations would allow several new and optimized observation types; in particular, it will allow many collaborative observation opportunities with other missions and with ground- and space-based observatories. Of particular note are joint observations with James Webb Space Telescope, for which dedicated observations of Mars are due to be conducted in 2022-2023. Science goals include mapping of the water D/H ratio, search for trace gases including methane, and mapping of thermospheric structure using 4.3 ÎŒm CO2 emission; the full-disk views provided by JWST are highly complementary to the vertical profiling and long temporal coverage provided by MEx and TGO
Geography, private costs and uptake of screening for abdominal aortic aneurysm in a remote rural area
BACKGROUND: The relationship between geographical location, private costs, health provider costs and uptake of health screening is unclear. This paper examines these relationships in a screening programme for abdominal aortic aneurysm in the Highlands and Western Isles of Scotland, a rural and remote area of over 10,000 square miles. METHODS: Men aged 65â74 (n = 9323) were invited to attend screening at 51 locations in 50 settlements. Effects of geography, deprivation and age on uptake were examined. Among 8,355 attendees, 8,292 completed a questionnaire detailing mode of travel and costs incurred, time travelled, whether accompanied, whether dependants were cared for, and what they would have been doing if not attending screening, thus allowing private costs to be calculated. Health provider (NHS) costs were also determined. Data were analysed by deprivation categories, using the Scottish Indices of Deprivation (2003), and by settlement type ranging from urban to very remote rural. RESULTS: Uptake of screening was high in all settlement types (mean 89.6%, range 87.4 â 92.6%). Non-attendees were more deprived in terms of income, employment, education and health but there was no significant difference between non-attendees and attendees in terms of geographical access to services. Age was similar in both groups. The highest private costs (median ÂŁ7.29 per man) and NHS screening costs (ÂŁ18.27 per man invited) were observed in very remote rural areas. Corresponding values for all subjects were: private cost ÂŁ4.34 and NHS cost ÂŁ15.72 per man invited. CONCLUSION: Uptake of screening for abdominal aortic aneurysm in this remote and rural setting was high in comparison with previous studies, and this applied across all settlement types. Geographical location did not affect uptake, most likely due to the outreach approach adopted. Private and NHS costs were highest in very remote settings but still compared favourably with other published studies
What causes hidradenitis suppurativa? - 15 years after
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30?April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote "Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy." (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as ?the only inflammatory skin disease than can be healed?. This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future
Variability in prostate and seminal vesicle delineations defined on magnetic resonance images, a multi-observer, -center and -sequence study
ABUNDANCES, STELLAR PARAMETERS, AND SPECTRA FROM THE SDSS-III/APOGEE SURVEY
The SDSS-III/Apache Point Observatory Galactic Evolution Experiment (APOGEE) survey operated from 2011â2014 using the APOGEE spectrograph, which collects high-resolution (R ~ 22,500), near-IR (1.51â1.70 ”m) spectra with a multiplexing (300 fiber-fed objects) capability. We describe the survey data products that are publicly available, which include catalogs with radial velocity, stellar parameters, and 15 elemental abundances for over 150,000 stars, as well as the more than 500,000 spectra from which these quantities are derived. Calibration relations for the stellar parameters (Teff , log g, [M/H], [a/M]) and abundances (C, N, O, Na, Mg, Al, Si, S, K, Ca, Ti, V, Mn, Fe, Ni) are presented and discussed. The internal scatter of the abundances within clusters indicates that abundance precision is generally between 0.05 and 0.09 dex across a broad temperature range; it is smaller for some elemental abundances within more limited ranges and at high signal-to-noise ratio. We assess the accuracy of the abundances using comparison of mean cluster metallicities with literature values, APOGEE observations of the solar spectrum and of Arcturus, comparison of individual star abundances with other measurements, and consideration of the locus of derived parameters and abundances of the entire sample, and find that it is challenging to determine the absolute abundance scale; external accuracy may be good to 0.1â0.2 dex. Uncertainties may be larger at cooler temperatures (Teff < 4000 K). Access to the public data release and data products is described, and some guidance for using the data products is provided
The Apache Point Observatory Galactic Evolution Experiment (APOGEE)
The Apache Point Observatory Galactic Evolution Experiment (APOGEE), one of the programs in the Sloan Digital Sky Survey III (SDSS-III), has now completed its systematic, homogeneous spectroscopic survey sampling all major populations of the Milky Way. After a three-year observing campaign on the Sloan 2.5 m Telescope, APOGEE has collected a half million high-resolution (R ~ 22,500), high signal-to-noise ratio (>100), infrared (1.51â1.70 ÎŒm) spectra for 146,000 stars, with time series information via repeat visits to most of these stars. This paper describes the motivations for the survey and its overall designâhardware, field placement, target selection, operationsâand gives an overview of these aspects as well as the data reduction, analysis, and products. An index is also given to the complement of technical papers that describe various critical survey components in detail. Finally, we discuss the achieved survey performance and illustrate the variety of potential uses of the data products by way of a number of science demonstrations, which span from time series analysis of stellar spectral variations and radial velocity variations from stellar companions, to spatial maps of kinematics, metallicity, and abundance patterns across the Galaxy and as a function of age, to new views of the interstellar medium, the chemistry of star clusters, and the discovery of rare stellar species. As part of SDSS-III Data Release 12 and later releases, all of the APOGEE data products are publicly available
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Background
Localised prostate cancer is commonly treated with external beam radiotherapy and moderate hypofractionation is non-inferior to longer schedules. Stereotactic body radiotherapy (SBRT) allows shorter treatment courses without impacting acute toxicity. We report 2-year toxicity findings from PACE-B, a randomised trial of conventionally fractionated or moderately hypofractionated radiotherapy versus SBRT.
Methods
PACE is an open-label, multicohort, randomised, controlled, phase 3 trial conducted at 35 hospitals in the UK, Ireland, and Canada. In PACE-B, men aged 18 years and older with a WHO performance status 0â2 and low-risk or intermediate-risk histologically-confirmed prostate adenocarcinoma (Gleason 4â+â3 excluded) were randomly allocated (1:1) by computerised central randomisation with permuted blocks (size four and six), stratified by centre and risk group to control radiotherapy (CRT; 78 Gy in 39 fractions over 7·8 weeks or, following protocol amendment on March 24, 2016, 62 Gy in 20 fractions over 4 weeks) or SBRT (36·25 Gy in five fractions over 1â2 weeks). Androgen deprivation was not permitted. Co-primary outcomes for this toxicity analysis were Radiation Therapy Oncology Group (RTOG) grade 2 or worse gastrointestinal and genitourinary toxicity at 24 months after radiotherapy. Analysis was by treatment received and included all patients with at least one fraction of study treatment assessed for late toxicity. Recruitment is complete. Follow-up for oncological outcomes continues. The trial is registered with ClinicalTrials.gov, NCT01584258.
Findings
We enrolled and randomly assigned 874 men between Aug 7, 2012, and Jan 4, 2018 (441 to CRT and 433 to SBRT). In this analysis, 430 patients were analysed in the CRT group and 414 in the SBRT group; a total of 844 (97%) of 874 randomly assigned patients. At 24 months, RTOG grade 2 or worse genitourinary toxicity was seen in eight (2%) of 381 participants assigned to CRT and 13 (3%) of 384 participants assigned to SBRT (absolute difference 1·3% [95% CI â1·3 to 4·0]; p=0·39); RTOG grade 2 or worse gastrointestinal toxicity was seen in 11 (3%) of 382 participants in the CRT group versus six (2%) of 384 participants in the SBRT group (absolute difference â1·3% [95% CI â3·9 to 1·1]; p=0·32). No serious adverse events (defined as RTOG grade 4 or worse) or treatment-related deaths were reported within the analysis timeframe.
Interpretation
In the PACE-B trial, 2-year RTOG toxicity rates were similar for five fraction SBRT and conventional schedules of radiotherapy. Prostate SBRT was found to be safe and associated with low rates of side-effects. Biochemical outcomes are awaited
- âŠ